Characterizing Kidney and Liver Cysts in Monoallelic PKHD1 Individuals Identified in a Population-Based Study
Doaa E. Elbarougy(Mayo Clinic), Peter C. Harris(Mayo Clinic), Tabinda Jawaid(Mayo Clinic), Timothy L. Kline(Mayo Clinic), Adriana Gregory(Mayo Clinic), Fouad T. Chebib(University Medical Center Groningen), Vicente E. Torres(Mayo Clinic in Arizona), Christian Hanna(Mayo Clinic), Shannon K. McDonnell(Mayo Clinic), Hana Yang(Mayo Clinic), Jacob A. Frank(Mayo Clinic), Jun Ma(Harbin Institute of Petroleum), Nicholas B. Larson(Mayo Clinic in Florida)
Cited by 0
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
|Kidney International|2015|602
Mutations in GANAB , Encoding the Glucosidase IIα Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease
|The American Journal of Human Genetics|2016|463
Polycystin-2, the protein mutated in autosomal dominant polycystic kidney disease (ADPKD), is a Ca <sup>2+</sup> -permeable nonselective cation channel
|Proceedings of the National Academy of Sciences|2000|447
Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity
|Journal of Clinical Investigation|2012|444